Why Venofer®?
Actor portrayal
Can be used in both inpatient and outpatient settings
Stable in a syringe or infusion bag for 7 days at controlled room temperature. No refrigeration required for unopened vials1
Do not freeze.
From 100 mg up to 400 mg for adults, depending upon indication or patient type1
Contains iron sucrose and water for injection1
Approved for adult and pediatric (≥2 years old) patients with chronic kidney disease (CKD)1
Can be administered undiluted or diluted. May save time by not premixing in the pharmacy1
Vial closure is not made with natural rubber latex
No premedication and no test dose required, which may save time and medication costs2
Venofer® (iron sucrose) injection, USP is indicated for the treatment of IDA in adult and pediatric patients
2 years and older with CKD.1
Venofer Reliability
- Unsurpassed and uninterrupted supply since US product launch in 20003
- More than 100,000,000 mg supplied monthly, on average, since 20133
- Supplied in 50 mg, 100 mg, and 200 mg single-dose vials1
7-day Stability After Dilution1
Venofer offers 7-day stability at controlled room temperature in both plastic syringes and IV admixtures diluted with 0.9% Sodium Chloride Injection (NaCl), avoiding potential waste.
- Do not dilute in concentrations below 1 mg/mL
- Do not mix Venofer with other medications
- Do not add Venofer to parenteral nutrition solutions
Concentration
Controlled Room Temperature
(25°C ± 2°C)
Refrigerated
(4°C ± 2°C)
Plastic
Syringe
- 2 mg—10 mg elemental iron per mL
- 20 mg elemental iron per mL (undiluted)
IV Admixture
(PVC and non-PVC)
- 1 mg—2 mg elemental iron per mL
Plastic Syringe
IV Admixture (PVC and non-PVC)
Concentration
- 2 mg—10 mg elemental iron per mL
- 20 mg elemental iron per mL (undiluted)
- 1 mg—2 mg elemental iron per mL
Controlled Room
Temperature (25°C ± 2°C)
Refrigerated (4°C ± 2°C)
Inside the Circulatory System4
Venofer is formulated as an iron-carbohydrate complex that consists of a mineral core (the iron) surrounded by a carbohydrate shell. The function of the carbohydrate shell is to stabilize the complex. According to the proposed mechanism, once IV iron is administered, these stable complexes are endocytosed by macrophages of the reticuloendothelial system, and the iron is transported to where it is needed.
Venofer
Erythroids
Red blood cells
Available in the Following Sizes and Strengths
NDC#
Strength (each mL contains 20 mg of elemental iron)
Supplied As
Shelf Pack
0517-2310-05
200 mg
10 mL
Single-Dose Vial
5
0517-2325-10
50 mg
2.5 mL
Single-Dose Vial
10
0517-2340-10
100 mg
5 mL
Single-Dose Vial
10
0517-2340-25
100 mg
5 mL
Single-Dose Vial
25
NDC# 0517-2310-05
Strength (each mL contains 20 mg of elemental iron)
200 mg
Supplied As
10 mL Single-Dose Vial
Shelf Pack
5
NDC# 0517-2325-10
Strength (each mL contains 20 mg of elemental iron)
50 mg
Supplied As
2.5 mL Single-Dose Vial
Shelf Pack
10
NDC# 0517-2340-10
Strength (each mL contains 20 mg of elemental iron)
100 mg
Supplied As
5 mL Single-Dose Vial
Shelf Pack
10
NDC# 0517-2340-25
Strength (each mL contains 20 mg of elemental iron)
100 mg
Supplied As
5 mL Single-Dose Vial
Shelf Pack
25
REFERENCES
1. Venofer (iron sucrose) injection, USP. Package Insert. American Regent, Inc.
2. Data on File. Iron Sucrose Periodic Safety Update Report, 2023. American Regent, Inc.
3. Data on File. IQVIA. NSP Audit from March 2017 to February 2023.
4. Geisser P, Burckhardt S. The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics. 2011;3(1):12-33.